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Summary.-We have studied the quantitative pharmacokinetic differences of indi-
vidual metabolites and unchanged cyclophosphamide (CPA) in control and pheno-
barbital-treated animals, using radiolabelled CPA together with thin-layer
chromatography. On Day 0, one group was started on phenobarbital drinking water
and one group stayed on regular acid water. P388 leukaemia, (106 cells i.p.) was
administered to all mice on Day 8, and 2 days later both groups of mice were given
i.p. CPA (200 mg/kg) with 14C.CPA (0 2 ,uCi per mouse). At 5-60 min after CPA
administration, groups of 10 mice were killed and their blood collected for assay of
parent compound and metabolites in plasma. Phenobarbital pretreatment reduced
CPA and phosphoramide mustard CXT (concentration x time) by 66+% and 27+%,
respectively. Assuming that phosphoramide mustard is both the ultimate cytotoxic
form of CPA and the blood-transport form, the reduction of CXT by phenobarbital
would predict a decreased therapeutic effect. The assay methods in this study will be
used in the future to determine the importance of this potential drug interaction in
man.
THE PATIENT with advanced cancer is
treated with a number of supportive
medications which may alter hepatic
enzyme activity and, consequently, may
influence the metabolism and antitumour
effects of certain anticancer agents (e.g.
cyclophosphamide (CPA) and adriamycin)
(Alberts and van Daalen Wetters, 1976;
Field et al., 1972; Garratini et al., 1975;
Hart and Adamson, 1969; Jao, et al.,
1972; Reich and Bachur, 1976; Sladek,
1972). We have been studying the under-
lying mechanisms and quantitating the
effects on tumour and normal tissue
toxicity of potentially efficacious or dele-
terious interactions between CPA and
routine medications. Recognition of such
deleterious drug interactions may prove
important in the design of dosage schedule
of CPA and other anticancer agents.
CPA requires enzymatic oxidation in
vivo to generate alkylating moieties. The
drug is activated by hepatic microsomal
enzymes, andthe activemetabolitereaches
target sites through systemic circulation.
The complex mode of activation and the
identification of metabolites of this agent
have been the subject of intense study by
several laboratories (Alarcon and Meien-
hofer, 1971; Colvin, et al., 1973; Norpoth,
1969; Sladek, 1973; Voelcker et al., 1976)
and the metabolic scheme elucidated by
these investigations is summarized in
Fig. 1.
Phenobarbital increases hepatic mixed-
function-oxidase activity of microsomes
and has been shown to decrease total
alkylating activity (Friedman and Boger,
1961) of plasma from CPA-treated mice
(Alberts and van Daalen Wetters, 1976;
Field et al., 1972; Garratini et al., 1975).
Simultaneous decreases were observed in
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antitumour effect in some studies (Alberts
and van Daalen Wetters, 1976; Field et al.,
1972; Garratini et al., 1975) but not in
others (Hart and Adamson, 1969; Sladek,
1972). Because of the correlation we
observed earlier (Alberts and van Daalen
Wetters, 1976) between phenobarbital
enzyme induction and decreased cell
killing against P388 leukaemia in DBA/2
mice, we have now studied the quantita-
tive pharmacokinetic differences in plasma
levels of individual metabolites and un-
changed drug in control andphenobarbital-
treated animals, using radiolabelled CPA,
in an attempt to correlate levels of parent
drug and cytotoxic metabolites with the
reduction in antitumour effect we observed
earlier. This method is superior to obser-
vation of total plasma alkylating activity
by theFriedman-Bogermethod (Friedman
and Boger, 1961) because the latter
method, as normally applied, does not
clearly differentiate between agents that
alkylate at physiological temperature and
pH and those that do not, and, even more
importantly, does not assess relative
contributions of activated, potentially-
active, and deactivated species.
MATERIALS AND METHODS
Radioactive cyclophosphamide.-14C-side-
chain-labelled CPA was kindly supplied by
Dr. Robert R. Engle, Head of Chemical
Resources Section, National Cancer Institute,
Silver Spring, Md, and was purified by thin-
layer chromatography. Sp. act. was 24
,uCi/mg after purification.
Mice.-Six- to 8-week-old male DBA/2
mice (The Jackson Laboratory, Bar Harbor,
Maine) weighing,, 20 g were used in these
experiments .
Chemotherapeutic agents-.Sodium pheno-
barbital (U.S.P. Crystalline, Mallinckrodt,
St. Louis, Mo.) in parenteral form was
brought to a final concentration of0 5 mg/ml
of solution by the addition of acid water.
CPA (Mead Johnson, Evansville, Indiana)
was dissolved in sterile water in the desired
concentration and 14C-CPA (0-2 ,tCi per
mouse) was added.
The administration schedule of chemo-
therapeutic agents-.Mice were divided into
2 groups of 10 animals. On Day 0, one group
was started on phenobarbital drinking water
and one group stayed on acid water (McPher-
son, 1963). P388 leukaemia, (106 cells i.p.)
was administered to all mice on Day 8. On
Day 10 both groups of mice received i.p.
CPA (4 mg per mouse or 200 mg/kg body wt)
together with 14C-CPA (0.2 ,uCi per mouse).
Mice averaged 2
-5 ml/day ofeither acid water
orphenobarbital drinking water, sothat, daily
total phenobarbital dosage averaged 1 25 mg
or r 62 -5 mg/kg.
To prove microsomal enzyme induction,
control and phenobarbital-pretreated mice
underwent sleep-duration studies after pento-
barbital administration. Pentobarbital, at a
dose of 45 mg/kg, caused acid-water-fed mice
to sleep between 25 and 45 min. Those
animals pretreated with phenobarbital either
did not sleep or rarely slept beyond 5 to 8 min
following pentobarbital injection.
Collection of plasma.-At each sampling
time after CPA administration (5, 10, 15, 20,
45, 60 min) groups of 10 mice were killed by
decapitation and their blood collected in iced,
heparinized centrifuge tubes. The blood sam-
ples were centrifuged at 2000 rev/min for
10 min at 4°C, and the resulting 25 ml of
plasma (for each group of 10 mice) was
immediately separated and frozen at -20°C.
Preparation ofmetabolitefractions.-Plasma
fractions were allowed to thaw and immedi-
ately extracted with chloroform (3 x 10 ml)
followed by methanol (10 ml), leaving a small
solid residue that was removed by filtration.
The residue was extracted with methanol
(2 x 10 ml) by trituration and filtration, and
the filtrates were combined with the first
methanol extract. Chloroform extracts were
evaporated to dryness at wateraspiratorpres-
sure and stored at -20°C. Methanol extracts
were treated with excess diazomethane, allow-
ed to stand 10 min at room temperature,
evaporated in a stream of N2, and stored at
-200C.
Thin-layer chromatography.-Analysis of
plasma fractions was performed in duplicate
(halfofthe total extract being applied to each
of 2 plates) on Analtech (Newark, Dela-
ware) precoated silica-gel G plates (250 ,um
thickness) in acetone: chloroform (3:1, v/v)
for non-polar metabolites and in chloro-
form: methanol (9:1, v/v) for polar metabo-
lites. Plates were activated by heating 1 h at
100°C and storing in a dessicated cabinet.
Isolation of metabolites.-Thin-layer chro-
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matograms were sprayed with a 1% solution
of4-(p-nitrobenzyl)pyridine (NBP) inacetone,
heated in an oven for 15 min at 140^C, and
sprayed with a 30 solution of KOH in
methanol. Alkylating components yielded
blue spots. Our previous studies (Struck
et al., 1975) had identified the alkylating
components, and use of synthetic standards
permitted identification and collection of
individual metabolites.
Radioactivity determination. Thin-layer
chromatographie spots were collected from
the plates and analysed for radioactivity in
AQUASOL (New England Nuclear, Boston,
Mass.) after solubilization in methanol w%vith
a Packard TRI-CARB Model 3315.
Pharmnacokinetic analysis. The trapezoidal
rule was used to measure the areas under the
parent-compound and metabolic-plasma-de-
cay curves.
RESULTS
A cyclophosphamide (CPA) dose of
200 mg/kg was selected for these studies
because it could be sensitively and repro-
ducibly assayed and because we and others
had previously used it in mouse studies
with this drug (Alberts and van Daalen
Wetters, 1976; Field et al., 1972).
Extraction of plasma from mice treated
with CPA with chloroform followed by
methanol consistently removed 9500
of the radioactivity, as illustrated for a
single experiment (30 min after drug
treatment) in Table I, leaving a non-
alkylating residue and indicating that the
unextracted radioactivity did not consist
of alkylating metabolites. Similar results
TABLE I. Relative radioactivity of extracts
ofplasmafromn cyclophosphamide (CPA)-
treated rnice*
Sample
Chloroform
Extract
Methanol
Extract
Residue
Control
Radio-
activity (0o)
527-
42
5 2
Phei
Prel
act-
*Blood was collected 30 min after dru1
nobarbital
treatment
Radio-
ivity (%O)
45 .9
48-7
5 4
g treatment.
E
m
.L
c
0
a
-t:
c
0
u
c
0
Time (min)
FIa. 2. Total plasma levels of CPA and its
alkylating metabolites in mice. --No
phenobarbital pretreatment;
Phenobarbital pretreatment.
were obtained earlier with whole blood
(Struck et al., 1975). At each sampling
time, recovery of radioactivity in the 3
fractions amounted to 0 5-1% of the
administered dose. Contrasting with these
radioactivity results, in every experiment
relative alkylating activity of chloroform
(non-polar) extracts was much greater
than that of methanol (polar) extracts, as
judged by colour formation of equivalent
amounts of the 2 extracts reaction with
NBP (Struck et al., 1975). This observation
emphasizes the relatively large amount of
non-alkylating, polarmetabolites inmetha-
nol extracts, although radioactivity differ-
ences were small.
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plasma levels of unchanged CPA and its
alkylating metabolites is illustrated in
Fig. 2. Phenobarbital pretreatment pro-
duced consistently lower levels of parent
TABLE II.-Comparative pharmacokinetics
of cyclophosphamide (CPA) and its alky-
lating metabolites before and after pheno-
barbital microsomal enzyme induction
Total CPA
and Metabs.
CPA
4-Keto CPA
PMt
CPt
Area under plasma decay
curves (,ug min/ml) ~~~~A
Acid- Phenobarbital
Water water
Control 62-5 mg/kg* Ratio
(1) (2) 2:1
821 527 0-64
402 131 0-33
267 294 1*10
36 26 0-72
7 5 0-71
*Daily for 10 days
tPhosphoramide mustard
tCarboxyphosphamide
t--
E
.
c
0
0
Time (min)
FIG. 3.-Plasma levels of CPA and its major,
non-polar metabolites in mice. No
phenobarbital pretreatment; Phe-
nobarbital pretreatment; CPA ((O); 4-
KetoCPA (EO); Nor-HN 2(A).
Time (min)
FiG. 4.-Plasma levels of minor, non-polar
metabolites of CPA in mice. - No
phenobarbital pretreatment; -- Phe-
nobarbital pretreatment; Dechloroethyl-
cyclophosphamide (0); Alcophosphamide
(ai).
compound and metabolites in plasma at
every sampling point after drug adminis-
tration, the area under the plasma decay
curve being only 58 -8% of that found for
control mice (Table II). However,
differences in levels of the therapeutically
efficacious, alkylating components in the
non-polar fraction is emphasized when
total, major, non-polar metabolites are
fractionated. Results are show-n in Fig. 3.
CPA CXT for the phenobarbital group
were only 33*2% of those for control
mice, whereas levels of 4-ketoCPA, a
major non-polar, inactive, metabolite in
blood (Struck et al., 1975), were similar
for both groups (Table II).
Fractionation of two minor, non-polar
metabolites gave the results shown in
Fig. 4. More rapid clearance of these
metabolites in the phenobarbital group
is apparent.
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E
c
0
a)
Time (min)
FIG. 5.--Plasma levels of the major, polar
metabolites of CPA in mice. - No
Phenobarbital pretreatment; Pheno-
barbital pretreatment; Phosphoramide
mustard (0); Carboxyphos-phamide (0-1).
Use of a different thin-layer solvent
system has resulted in separation of the
2, major, polar plasma metabolites, phos-
phoramide mustard and carboxyphos-
phamide. The methyl esters of these
metabolites were separable in chloroform:
methanol (9:1), giving Rf O, 0* 55 for
carboxyphosphamide methyl ester and
Rf 0 45 for phosphoramide mustard
methyl ester. Plasma levels are shown in
Fig. 5. Consistently higher levels of
phosphoramide mustard were observed
relative to carboxyphosphamide. How-
ever, peak levels of phosphoramide
mustard are much lower than those of
CPA and 4-ketoCPA. Again, CXT areas
for the control mice were higher than those
for phenobarbital mice (Table II).
DISCUSSION
By use of a previously described thin-
layer chromatographic method (Struck
et at., 1975), CPA and its alkylating
metabolites in chloroform and methanol
extracts of plasma from control and
22
phenobarbital-treated mice were fraction-
ated and identified by co-chromatography
with synthetic standards. The extraction
procedure recovered 95% of the radio-
activity in plasma after administration of
14C-side-chain-labelled CPA, as well as
complete removal of alkylating compon-
ents, as demonstrated by reaction of the
extract residues with 4-p-(nitrobenzyl
pyridine. This high recovery of radio-
activity demonstrates that little covalent
binding ofCPA or its metabolites contain-
ing the labelled moiety occurs with plasma
components, and assures that all major
metabolites are available in the 2 extracts
for identification and quantitation. Iden-
tical results were obtained in previous
studies (Struck et al., 1975) with both
ring- and side-chain-labelled drug.
Thin-layer chromatograms in this study
were qualitatively identical to those
observed in our earlier studies on pooled
blood samples (Struck et al., 1975) and
on blood samples from 40 individual
mice (Struck, et al., 1977). The earlier,
extensive investigation of individual
metabolite fractions by mass spectro-
metric analysis had confirmed the identity
of the metabolites, and had revealed that
otherchlorine-containing, similarlyvolatile
metabolites were not present in these
fractions, at least in sufficient concentra-
tion to reveal chlorine-isotope peaks that
were distinguishable from other peaks in
the mass spectra (Struck et at., 1975).
Furthermore, since the spectrum of meta-
bolites observed in this study was identical
to that in our earlier studies (Struck et al.,
1975; Struck et al., 1977) and in studies by
others by different methods (Bakke et al.,
1972; Colvin et al., 1976; Connors et al.,
1974; Voelcker et al., 1976), the likelihood
of significant contamination by other, yet
unidentified metabolites is low. It is
emphasized that, although the electron-
impact mass spectral method used in our
earlier studies would not confirm the
presence of 4-hydroxyCPA, a synthetic
specimen was used as a chromatographic
standard in this and the earlier studies
(Struck et al., 1975; Struck et al., 1977 and
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this metabolite was not detected in this
or in any of the earlier studies. The limit
of detection of the alkylating metabolites
of CPA by our method is 0 1 Hg; for the
volume of plasma used in this study
(2.5 ml) the limit ofdetection for duplicate
determinations would be approximately
0 08 ,ug/ml. In earlier studies (Struck et
al., 1975) which used 12 5 ml of blood or
at least 5 ml equivalents of plasma, the
limit of detection would be approximately
0a04 pg/ml for duplicate determinations.
Of interest is a recent report by Wagner
et al., (1977) of levels of stabilized 4-hy-
droxyCPA (0.14-0 42 Mtg/ml) higher than
the limiting values cited above, in blood of
humans 2 h after an i.v. dose of CPA of
only 10 mg/kg, whereas our present and
previous studies used doses of 100-300
mg/kg. It is possible, however, that
degradation of any 4-hydroxyCPA in our
samples could have occurred before
chromatography, since stabilization was
not attempted. Future studies will employ
one or both of the reported stabilization
techniques (Fenselau et al., 1977; Wagner
et al., 1977) to attempt quantitation of
this metabolite, whose role in the overall
cytotoxic effect of CPA in vivo is still
unresolved (Cox et al., 1975; Fenselau
et al., 1977; Struck et al., 1975; Wagner
et al., 1977).
The effect ofphenobarbital oIn CPA rnet-
abolism has been investigated by several
groups (Alberts and van Daalen Wetters
1976; Field et al., 1972; Garratini et al.,
1975; Hart and Adamson, 1969; Jao
et al., 1972; Sladek, 1973). However,
none of these prior studies included
quantitation of individual polar and non-
polar metabolites. In this study we have
identified and quantitated 4-ketoCPA,
nor-nitrogen mustard, dechloroethyl-CPA,
"alcophosphamide" 13-hydroxypropyl
N,N - bis (2 - chloroethyl )phosphorodiami-
dase}, phosphoramide mustard, and
carboxyphosphamide, as well as parent
drug, in plasma of phenobarbital-treated
and control mice over a range of time
(5-60 min).
An interesting difference at the shorter
sampling times between this study and
our prior study is the consistently lower
levels of the total of unchanged drug and
alkylating metabolites in this study (Figs.
2, 3, 4) compared to higher total plasma
alkylating activity in the prior study
(Alberts and van Daalen Wetters, 1976).
This difference may be the result of the
method used (Friedman and Boger, 1961)
for determination of plasma alkylating
activity; themethod quantitates alkylation
at 100°C for 25 min in acid and is clearly
not physiological. As a result, the Fried-
man-Boger method mnay inaccurately ref-
lect potential alkylating components in
plasma at 37°C and pH 7.
In previous studies (Connors et al., 1974;
Struck et al., 1975) all the non-polar
metabolites and one polar metabolite
(carboxyphosphamide) identified and
quantitated in this study were shown to
be inactive as antitumour agents. Conse-
quently Fig. 2, which reflects total levels
of CPA and its alkylating metabolites, is
misleading as an indication of levels of
components potentially able to produce
an antitumour effect, since it includes
metabolites known to be ineffective. Of all
the alkylating, radioactive components
isolated and identified in the non-polar
fraction, only CPA is potentially capable
(through subsequent conversion to
4-hydroxyCPA and phosphoramide
mustard) of killing tumour cells. There-
fore Fig. 3 and Fig. 5, insofar as they
show levels of CPA and phosphoramide
mustard, are better indicators of the
reason for differences in tumour response
to CPA, with and without phenobarbital
pretreatment.
Peak plasma levels of phosphoramide
mustard, probably the ultimate intracel-
lular cytotoxic form of CPA (Colvin et al.,
1973; Connors et al., 1974; Struck et al.,
1971) [although there is disagreement
about the role of this metabolite as a
blood transport form in producing the
cytotoxic effect of cyclophosphamide (Col-
vin et al., 1976; Cox et al., 1975; Hohorst
et al., 1976; Struck et al., 1975)] and
carboxyphosphamide are low (5-10%) in
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comparison with peak levels of CPA.
Data presented in Fig. 5 represent the first
quantitation of levels of phosphoramide
mustard in mouse plasma after CPA
treatment. Voeleker et at. (1976) quanti-
tated this metabolite, along with some
unidentified metabolites in rat serum, and
observed similar levels relative to CPA,
and quantitation in human plasma has
recently been accomplished (M. Colvin,
personal communication). Differences in
levels of phosphoramide mustard between
the phenobarbital and control groups are
small during the first 20 min, after which
somewhat higher levels of phosphoramide
mustard persist for the remaining 40 min
of the study in the control group. It is
tempting to speculate that his persistence
is the cause of the improved (1 log) cell
killing observed in our earlier work
(Alberts and van Daalen Wetters, 1976)
against the very responsive P388 leukae-
mia. Indeed,ifitistruethattheantitumour
effect of a cell cycle-nonspecific chemo-
therapeutic agent correlates with the
plasma CXT area of the active form of a
drug (Jao et al., 1972; Jusko, 1971;
Sladek, 1972) and if phosphoramide mus-
tard is accepted as both the ultimate
cytotoxic form of the drug and as the
blood-transport form, the areas of control
and phenobarbital groups, which indicate
a 39% greater area for the control, would
predict a decreased therapeutic effect.
Whether such a difference is true for
humans has not been determined, but
should be evaluable by the methods used
in this study.
This investigation was supported in part by the
Medical Oncology Program Project Grant CA-17094
(to the University ofArizona) and by Contract No 1-
CM-43762 (to Southern Research Institute) from
the National Cancer Institute, National Institutes
of Health, Bethesda, Maryland, and by the General
Research Service of the University of Arizona
Health Science Center.
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